Post results conference call with investors/ analysts
Cadila Healthcare Ltd has informed BSE about Post results conference call with investors/ analysts.19-10-2016
19-10-2016
Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended September 30, 2016
Cadila Healthcare Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended September 30, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.12-10-2016
Shareholding for the Period Ended September 30, 2016
Cadila Healthcare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2016. For more details, kindly Click here12-10-2016
Q2 results on Oct 26, 2016
Cadila Healthcare Ltd has informed BSE that the meeting of the Board of Directors of the Company will be held on October 26, 2016, inter alia, to consider to approve the unaudited financial results for the quarter / half year ended on September 30, 2016 (Q2).Further, as per Code of Conduct for prevention of Insider Trading adopted by the Company under SEBI (Prohibition of Insider Trading) Regulations, 2015, the Trading Window shall remain...07-10-2016
Zydus signs in-licensing deal with Neovii of Switzerland
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated October 06, 2016 titled "Zydus signs in-licensing deal with Neovii of Switzerland".06-10-2016
Zydus and Medicines for Malaria Venture Sign Agreement to Develop Potential New Antimalarial Drug
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated September 30, 2016 titled "Zydus and Medicines for Malaria Venture Sign Agreement to Develop Potential New Antimalarial Drug".30-09-2016
Zydus Cadila ties up with Takeda to develop chikungunya vaccine
Drug firm Zydus Cadila today announced partnership with Japan's Takeda Pharmaceutical Company Ltd to develop a vaccine for chikungunya. The broad-based agreement includes early stage development to20-09-2016
Zydus and Takeda enter into partnership to address emerging infectious diseases
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated September 20, 2016 titled "Zydus and Takeda enter into partnership to address emerging infectious diseases"20-09-2016
Cadila Healthcare gains on EIR for Ahmedabad facility
The stock moved higher by 4% to Rs 391 on the BSE.02-09-2016
Updates
Cadila Healthcare Ltd has informed BSE that the Company's Oral Solid Dosage drug manufacturing plant located at SEZ, Ahmedabad has received an Establishment Inspection Report (EIR) from the USFDA following the inspection carried out in January 2016. The receipt of EIR indicates the successful closure of the inspection points (483s) raised. It may be mentioned that this plant is a separate manufacturing unit and does not form a part of the Moraiya formulations manufacturing facility.02-09-2016